http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
-
PTC Therapeutics (PTCT) Reports Negative CHMP Opinion for Renewal of Conditional Marketing Authorization for Translarna
-
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
-
PTC Therapeutics (PTCT) Provides an Update on Commercial Progress and R&D Pipeline
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics (PTCT) Provides Updates on Translarna Regulatory Activities
-
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
-
PTC Therapeutics (PTCT) Announces Evrysdi Royalty Agreement with Royalty Pharma for Up To $1.5B
-
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
-
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results
-
PTC Therapeutics (PTCT) Announces 25% Workforce Cut
-
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
-
PTC Therapeutics' (PTCT) Translarna Receives Negative CHMP Opinion
-
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
-
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
-
PTC Therapeutics (PTCT) Announces CHMP Recommends Evrysdi for Babies Under Two Months Old with Spinal Muscular Atrophy
-
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
-
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
-
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics (PTCT) Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
-
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
-
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
-
PTC Therapeutics (PTCT) Reports Results from MIT-E Clinical Trial of Vatiquinone
-
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
-
PTC Therapeutics (PTCT) Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
-
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics (PTCT) Vatiquinone MOVE-FA Registration-Directed Trial Did Not Meet Its Primary Endpoint
-
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
-
PTC Therapeutics (PTCT) Announces Strategic Pipeline Prioritization
-
PTC Therapeutics Announces Strategic Pipeline Prioritization
-
PTC Therapeutics (PTCT) Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
-
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
-
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
-
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
-
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
PTC Therapeutics (PTCT) Announces CEO Resignation
-
Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
-
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results